Clinical Outcomes of Chemo-Immunotherapy for Extensive Stage Small Cell Lung Cancer: A Real-World Single Centre Study in Portugal
Acta Médica Portuguesa · 2025
DOI: 10.20344/amp.22546 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Médica Portuguesa, 2025. Verfasst von David Noivo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonology Department. Unidade Local de Saúde Arrábida. Setúbal. Portugal. Hauptthemen laut MEDLINE: Lung Neoplasms, Small Cell Lung Carcinoma, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Small cell lung cancer (SCLC) is an aggressive type of lung cancer. Recent studies have provided a new hope by adding atezolizumab to the standard treatment of extensive disease SCLC (E-SCLC). The aim of our study was to evaluate the real-life performance of atezolizumab plus chemotherapy in extensive stage SCLC in a Portuguese setting. Data was collected on twenty patients (70% were male with a mean age of 66.9 years) in treatment at a tertiary hospital in Portugal with E-SCLC treated with chemotherapy and atezolizumab between July 2022 and February 2024. All patients received a carboplatin plus etoposide regimen in combination with atezolizumab. The overall response rate was 55% (95% CI: 31.5 – 76.9) and the disease control rate was 70% (95% CI: 45.7 – 88.1). The median overall survival (OS) and progression-free survival (PFS) was 9.7 (95% CI:5.08 – 14.32) and 7.17 (95% CI:3.28 – 11.05) months, respectively. In total, 13 (65%) patients experienced disease progression and 10 (50%) died during follow-up from events related to the disease. Patients with a performance status score ≥ 2 had lower PFS (p = 0.003) and OS (p = 0.001). To the best of our knowledge, this is the first real-world clinical study in Portugal to evaluate real life outcomes for this combination therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pulmonology Department. Unidade Local de Saúde Arrábida. Setúbal. Portugal.
- Pulmonology Department. Unidade Local de Saúde Lisboa Norte. Lisbon. Portugal.
Zitieren
APA
Noivo, D., Bragança, M., Vilariça, A. S., Ferro, F., Lopes Machado, A., Hasmucrai, D., & Alves, P. (2025). Clinical Outcomes of Chemo-Immunotherapy for Extensive Stage Small Cell Lung Cancer: A Real-World Single Centre Study in Portugal. Acta Médica Portuguesa. https://doi.org/10.20344/amp.22546
Vancouver
Noivo D, Bragança M, Vilariça AS, Ferro F, Lopes Machado A, Hasmucrai D, et al. Clinical Outcomes of Chemo-Immunotherapy for Extensive Stage Small Cell Lung Cancer: A Real-World Single Centre Study in Portugal. Acta Médica Portuguesa. 2025. doi:10.20344/amp.22546
BibTeX
@article{Noivo2025,
author = {Noivo, David and Bragança, Maria and Vilariça, Ana Sofia and Ferro, Filipa and Lopes Machado, Andrea and Hasmucrai, Direndra and Alves, Paula},
title = {Clinical Outcomes of Chemo-Immunotherapy for Extensive Stage Small Cell Lung Cancer: A Real-World Single Centre Study in Portugal},
journal = {Acta Médica Portuguesa},
year = {2025},
doi = {10.20344/amp.22546}
}
EUVIMED